Pricing and Reimbursement of the Healthcare System in India

March 16, 2012 - PRLog -- One of the major reasons behind the increasing popularity of reference pricing is the increasing pressure felt by the reimbursement agencies for healthcare expenditures. Reference pricing allows] a country to set minimum possible rates for a particular drug. It is generally adopted for generic products and “me too” branded products for which comparable references are present in other geographical regions. Innovative products are generally excluded from reference pricing.

The National Pharmaceutical Pricing Authority (NPPA) has asked the government to negotiate the prices of patented medicines used by a central agency, based on a reference pricing system. The central agency should estimate the market potential of new patented drugs and negotiate their prices based on market levels where the purchasing power parity (PPP) and the per capita income of the people of India are comparable. A reference price should then be set based on the average or the lowest of the reference countries’ prices.

The annual turnover helps in identifying the drugs of mass consumption; the drugs are selected based on their annual consumption and demand as well as their annual revenues. This leads to the exclusion of those that may not be drugs of mass consumption but still critical or life-saving.

Demand elasticity varies with the form of payment; it is directly proportional to the OOP expenditures. The larger is the proportion of OOP expenditures, the larger the elasticity. In the case of medicines, the elasticity of demand would vary with the urgency of the situation. In all circumstances, the demand for medicines will be less elastic than that for many other consumer products. In the developing countries like India, spending on medicines comes largely from household resources, contributing substantially to OOP expenditures. Therefore, the demand for pharmaceuticals is stronger and less elastic in developed countries like the US and the UK, compared to India.

For Sample Pages, please click or add the below link to your browser:
http://www.gbiresearch.com/RequestSamplePages.aspx?ID=Pri...


GBI Research, the leading business intelligence provider, has released its latest research “Pricing and Reimbursement in India - Low Levels of Drug Reimbursement Lead to a High Out-Of- Pocket Expenditure”. It provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in India with a detailed analysis of the different regulatory mechanisms used in India. The report closely scrutinizes the major changes in pharmaceuticals related pricing and reimbursement in the recent past and the impact these changes will have in the future. The health insurance is responsible for facilitating demand by making the high-cost prescription drugs more affordable. Although the per capita income is rising in India, the modest income of most of the population keeps the high cost drugs and medicines unattainable. Drugs would become more costly with the enforcement of product patents and so sales of the expensive drugs depend on the growth and the maturity of the health insurance sector. If the health insurance industry does not mature, the market for patented drugs would experience adverse effects. The next three to five years will see significant growth and change in the Indian health insurance industry as new insurance players and insurance products respond to the increased demand.

GBI Research analyzes that the Indian pharmaceutical market is characterized by differences in prices for the same product and high profits, apart from marketing and the selling of unnecessary combinations. Drug pricing is an important issue confronting the Indian government. Due to intense competition, the drug prices are already the lowest in the world. The government should take a holistic view of healthcare costs and pursue a broader set of initiatives to ensure the access and affordability of the medicines to the common people.

For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=Pricing-and-Rei...

Visit our report store: http://www.gbiresearch.com
For more details contact:
pressreleases@gbiresearch.com            
North America:                   +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.